GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unicycive Therapeutics Inc (NAS:UNCY) » Definitions » Shareholder Yield %

Unicycive Therapeutics (Unicycive Therapeutics) Shareholder Yield % : -1.17% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Unicycive Therapeutics Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Unicycive Therapeutics's Shareholder Yield % was -1.17%.


Unicycive Therapeutics Shareholder Yield % Historical Data

The historical data trend for Unicycive Therapeutics's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unicycive Therapeutics Shareholder Yield % Chart

Unicycive Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shareholder Yield %
- - 1.62 21.52 -2.18

Unicycive Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.50 -1.67 -1.58 -2.18 -0.80

Competitive Comparison of Unicycive Therapeutics's Shareholder Yield %

For the Biotechnology subindustry, Unicycive Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unicycive Therapeutics's Shareholder Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Unicycive Therapeutics's Shareholder Yield % falls into.



Unicycive Therapeutics Shareholder Yield % Calculation

Unicycive Therapeutics's Shareholder Yield % for the quarter that ended in Mar. 2024 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0 %+0 %+-0.8 %
=-0.8 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Unicycive Therapeutics  (NAS:UNCY) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Unicycive Therapeutics Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of Unicycive Therapeutics's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Unicycive Therapeutics (Unicycive Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
4300 El Camino Real, Suite 210, Los Altos, CA, USA, 94022
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Executives
Sandeep Laumas director 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
John L Ryan director C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Sara Kenkare-mitra director C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gaurav Aggarwal director C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Douglas Jermasek other: EVP of Corporate Strategy 4300 EL CAMINO REAL, SUITE 210, LOS ALTOS CA 94022
Brigitte Schiller director UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
John Townsend officer: Chief Financial Officer 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Pramod Gupta officer: EVP, Pharmaceuticals and BD UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022
Shalabh K. Gupta director, officer: CEO UNICYCIVE THERAPEUTICS, INC., 5150 EL CAMINO REAL, SUITE A-32, LOS ALTOS CA 94022

Unicycive Therapeutics (Unicycive Therapeutics) Headlines

From GuruFocus